PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Benchmark Research, 3100 Red River St #2, Austin, TX 78705, United States.\', \'Moderna, Inc., 200 Technology Sq, Cambridge, MA 02139, United States.\', \'Moderna, Inc., 200 Technology Sq, Cambridge, MA 02139, United States. Electronic address: brett.leav@modernatx.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0264-410X(21)00153-510.1016/j.vaccine.2021.02.007
?:doi
?:hasPublicationType
?:journal
  • Vaccine
is ?:pmid of
?:pmid
?:pmid
  • 33707061
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.863
?:rankingScore_hIndex
  • 159
is ?:relation_isRelatedTo_publication of
?:title
  • A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all